- Lexaria will license in any of the 40 countries where its technology already has a patent or is patent-pending
- Company sees up to 80 percent of its future revenues coming from licensing DehydraTECH proprietary ingestion delivery technology
- DehydraTECH™ has applications for processed foods, tobacco industry, pharmaceutical companies, NSAIDs, supplements and beverages
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has a wide variety of licensing applications for its patented DehydraTECH™ delivery technology. It is already licensed to Nuka Enterprises LLC, maker of “1906” brand cannabis chocolates (http://cnw.fm/HD4bm). Chris Bunka, CEO, emphasizes that his company’s technology applies to far more than just the cannabis industry (http://cnw.fm/rPz6n), with the company indicating that it is also applicable to nicotine, NSAIDs, beverages, drugs and vitamins. LXRP forecasts that up to 80 percent of its total revenue could stem from licensing deals, the CEO added in a podcast interview with Uptick Newswire (http://cnw.fm/VB5jh).
Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology that promotes healthier ingestion methods. It results in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.
Its licenses are offered based upon geography, applications and product categories. LXRP’s patent portfolio protects its IP and is expanding. Last year, LXRP received its first U.S. patent on nicotine, ibuprofen and aspirin delivery, as well as cannabinoids. Bunka added that Lexaria’s technology is also in the active investigation phase in the EU, Canada, China, Japan and India.
The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products.
Lab tests on mice have shown a 50 percent improvement in active ingredients, such as nicotine, being absorbed into the bloodstream. They demonstrated even higher percentage levels absorbed into the brain. Bunka said that these results could potentially have an important impact on future treatment of cancer and brain tumors.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.cannabisnewswire.com